Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

5.2%

6 terminated/withdrawn out of 116 trials

Success Rate

82.4%

-4.1% vs industry average

Late-Stage Pipeline

21%

24 trials in Phase 3/4

Results Transparency

14%

4 of 28 completed trials have results

Key Signals

29 recruiting4 with results

Enrollment Performance

Analytics

Phase 2

44(55.0%)

Phase 3

22(27.5%)

N/A

7(8.8%)

Phase 1

5(6.3%)

Phase 4

2(2.5%)

80Total

Phase 2(44)

Phase 3(22)

N/A(7)

Phase 1(5)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (116)

Showing 20 of 116 trials

NCT04071704Completed

Assessing Health-related Quality of Life in Sarcoma Patients

Role: collaborator

NCT05821556Phase 2Recruiting

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

Role: lead

NCT07213557Phase 2Recruiting

Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy

Role: lead

NCT06880523Phase 2Recruiting

STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

Role: collaborator

NCT07522697Phase 2Not Yet Recruiting

Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4

Role: lead

NCT07290894Phase 2Recruiting

Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01

Role: lead

NCT07459920Phase 2Not Yet Recruiting

Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden

Role: lead

NCT07354165Recruiting

Financial Toxicity in Patients With Early-stage Breast Cancer

Role: lead

NCT07314853Not ApplicableNot Yet Recruiting

Using Artificial Intelligence to Guide Fluid Therapy During Major Cancer Surgery: A Randomized Controlled Trial

Role: lead

NCT07302451Phase 2Active Not Recruiting

REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)

Role: lead

NCT05817227Recruiting

Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.

Role: lead

NCT06218511Phase 1Active Not Recruiting

A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)

Role: lead

NCT06270602Recruiting

The ONCOCAMP Study

Role: lead

NCT07213570Phase 2Recruiting

STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

Role: lead

NCT06714357Phase 2Recruiting

ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer

Role: lead

NCT07269249Recruiting

Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer

Role: lead

NCT07267780Not Yet Recruiting

Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases.

Role: lead

NCT07027046Recruiting

Application of da Vinci SP for Endometrial Cancer Surgical Staging

Role: lead

NCT05818865Not ApplicableActive Not Recruiting

"Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+.

Role: lead

NCT06236464Recruiting

Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas

Role: lead